Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
May 07, 2026
May 07, 2026
WHIPPANY, New Jersey, May 7 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news on May 6, 2026:
* * *
Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline
* Perfuse Therapeutics' investigational lead program shows potential to become one of the first disease-modifying treatments for both Glaucoma and Diabetic Retinopathy (DR)
* High unme . . .
* * *
Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline
* Perfuse Therapeutics' investigational lead program shows potential to become one of the first disease-modifying treatments for both Glaucoma and Diabetic Retinopathy (DR)
* High unme . . .